Sanity Group GmbH (“Sanity Group”), one of Europe’s leading medical cannabis companies, today announced the successful completion of its strategic transaction with one of Canada’s leading licensed cannabis producers Organigram Global Inc (“Organigram”). With the closing, both companies enter the next phase of a their shared mission to build a globally leading pure-play cannabis company. Together, they intend to accelerate their international growth strategy and shape the development of the European cannabis market. “The completion of this transaction marks an important next step,” said Finn Hänsel, founder and CEO of Sanity Group. “With expanded capabilities in research and development as well as additional production capacity, we are now in a position to significantly accelerate and scale our activities in Germany and across Europe.”
As part of the transaction, Sanity Group has been valued at up to €250 million, consisting of an initial valuation of €130 million and up to an additional €120 million tied to defined performance metrics over a twelve-month period ending April 1, 2027. This positions the agreement among the largest transactions in the European cannabis and healthcare sector to date, as well as one of the most significant deals in Berlin’s startup ecosystem in recent years.
By joining forces, Sanity Group and Organigram combine their respective strengths across the value chain: Sanity Group’s deep market knowledge and regulatory expertise in Europe complement Organigram’s extensive experience as a licensed producer, as well as its innovation and production capabilities. The shared objective is to further strengthen their position in key European markets and unlock new growth opportunities. Sanity Group will continue to operate with its existing team and brands and will further scale its European platform. At the same time, pharmacy customers and partners will benefit from enhanced resources, international connectivity, and increased innovation capacity.
As part of the closing, Max Narr, former Managing Director and Chief Strategy & Investment Officer of Sanity Group and Managing Director of its subsidiary Endosane Pharmaceuticals, has been appointed to Organigram’s Board of Directors for the duration of the agreed earnout period, where he will support the continued development of the joint business. His appointment underscores the close strategic alignment between the two organizations and ensures representation of the European perspective at the group level.
Long-term Commitment to the European Market
“Sanity Group was founded on the conviction that a sustainable medical cannabis market will emerge in Europe, and that those companies best positioned to lead will be the ones that establish robust supply chains early, invest in authentic brands, and build deep regulatory expertise,” Hänsel added. “Our goal has always been to consistently build and strengthen that foundation. We look forward to taking the next steps together with Organigram and further expanding our position in a rapidly evolving market.”
From Organigram’s perspective, this marks the beginning of the next chapter in its global strategy: “The closing of this transaction is the beginning of the next chapter in what we have been building together for some time – the creation of a truly global cannabis company,” said James Yamanaka, CEO of Organigram. “Sanity Group has established a leading position in Germany and Europe through deep expertise and disciplined execution. This combination creates a company with the scale, infrastructure, and market presence to compete at the highest level in both Canada and Germany. I am proud of what both teams have achieved to reach this point and look forward to what we will build together going forward.”
Medical Cannabis Patient Care Remains a Core Focus
Sanity Group will continue to focus on medical cannabis, innovative product development, and scientific pilot projects, while expanding its activities in both existing and new European markets, including the United Kingdom, Poland, the Czech Republic, and Switzerland. “Patient care remains at the core of everything we do,” said Hänsel. “With the additional capabilities, we are now even better positioned to improve access to medical cannabis across Europe and further professionalize patient care.”
+++
For further information, particularly regarding financial and capital markets-related details of the transaction, please refer to Organigram’s press release.
Organigram Global and Sanity Group Announce Successful Closing of Acquisition
